5: Oxidative Stress and Disease

Disease, Aging and Oxidative Stress

U.S. government funded studies on antioxidants and disease conditions has more than doubled in the last year, to almost 300.  We now know that oxidative stress is a compounding factor in neurodegenerative diseases such as Alzheimer's, Parkinson's, ALS, Huntington's Disease, and Diabetic Neuropathy.  Oxidative stress is also a factor in cataracts, stroke, renal disease and arteriosclerosis.

The Free Radical Theory of Aging states that, over time, mitochondria accumulate damage to their genetic material.  The result is progressively fewer mitochondria capable of providing sufficient energy for optimal cell function.  This ultimately leads to cell death and physical aging.  Many of the diseases associated with oxidative stress are diseases that manifest with earlier in people with higher oxidative stress loads or a poor redox balance.

References

  1. Click here for more on the Free Radical Theory of Aging.
  2. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer Ab by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998; 273(21):12817-26.
  3. Brevetti G, Attisano T, Perna S, et al. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study. Angiology. 1989;40:857–862.
  4. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34:1618–1624.
  5. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992;13:251–255.
  6. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77:767–773.
  7. Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 1994;9:161-168.. Neuropsychobiology 1997;36:73-82.
  8. Bartels GL, et al. Anti-ischaemic efficacy of L-propionyl-carnitine—a promising novel metabolic approach to ischaemia? Eur Heart J. 1996;17:414–420.
  9. Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol. 1994;74:125–130.
  10. Bartels GL, et al. Additional anti-ischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc Drugs Ther. 1995;9:749–753.
  11. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res. 1990;10:355–360.
  12. Cipolli C, Chiari G. Effects of L-acetylcarnitine on mental deterioration in the aged: initial results [in Italian; English abstract]. Clin Ter. 1990;132:479–510.
  13. Cherchi A, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 1985;23:569–572.
  14. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Ab amyloid deposits by biometal depletion. J Biol Chem. 1999; 274(33):23223-8.
  15. Dal Negro R, Turco P, Pomari C, et al. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol. 1988;26:269–272.
  16. De la Torre JC. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology. 1997; 43(1-2):26-43.
  17. Davini P, Bigalli A, Lamanna F, et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res. 1992;18:355–365.
  18. Feinfeld DA, et al.: Effect of oral L-carnitine on serum myoglobin in hemodialysis patients. Ren Fail 1996 Jan;18(1):91-6
  19. Greco AV, Mingrone G, Bianchi M, et al. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: Controlled double blind trial versus placebo. Drugs Exp Clin Res. 1992;18:69–80.
  20. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res. 1990;16:101–106.
  21. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001;110:616–622.
  22. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of alzheimer Ab neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. 1999; 274(52):37111-6.
  23. Iliceto S, et al. Effect of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26:380–387.
  24. Kopke R, Bielefeld E, Liu J, et al. Prevention of impulse noise-induced hearing loss with antioxidants. Acta Otolaryngol 2005;125(3):235-43. PMID 15966690
  25. Lagioia R, Scrutinio D, Mangini SG, et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol. 1992;34:167–172.
  26. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003;18:61-71.
  27. Nakano T, Miyasaka M, Mori K, et al. Effects of idebenone on electroencephalograms of patients with cerebrovascular disorders. Arch Gerontol Geriatr 1989;8:355-366.
  28. Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther. 1991;13:2–21.
  29. Pela R, Calcagni AM, Subiaco S, et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999;66(6):495-500.
  30. Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J. 1994;15:1348–1352.
  31. Shivaram KN, Winklhofer-Roob BM, Straka MS, et al. The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria. Free Radic Biol Med 1998;25:480-492.
  32. Sloan RS, et al.: Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Am J Kidney Dis 1998 Aug;32(2):265-72
  33. Ungheri D, et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol 2000;13(3):123-128
  34. Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy. J Child Neurol. 1995;10(suppl 2):S45–S51.
  35. Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of two doses of idebenone in the treatment of Alzheimer's disease
  36. Xie J, et al.: The protective effect of L-carnitine on ischemia-reperfusion heart. Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, China.